Xena and Android I don't know if this helps with your discussion but here is a previous post of excerpts from the Alfred Group's annual report. I infer from this that the Australian government will be involved again for the P3 they anticipated for 2017.
Post #
86394
of 92731 Go
Funding? MacFarlane does the research at Caufield Hospital a unit of the Alfred Group in Australia. Here are some excerpts from Alfred Group's Annual Report 2015-16 published August 2016. This indicates that a great deal of funding comes from partnerships.
(Page 4 - Alfred Group annual Report 2015-16)
Chairperson and Chief Executive’s Year in Review (continued)
Discovering the next generation of care Partnerships continued to underpin significant research developments that informed clinical practice in Australia and overseas. Researchers from The Alfred answered the long-held debate over whether aspirin should be stopped before coronary artery surgery. The results of the 10-year international study showed no increased risk of surgical bleeding or need for blood transfusion associated with asprin use. Scientists from The Alfred and Monash University made a breakthrough in targeting aggressive blood cancers through combination therapy, giving hope to people suffering from Acute Myeloid Leukaemia. At our Caulfield campus, early research results from the international drug trial of Anavex 2-73, which aims to address the symptoms of dementia, were positive. Also significant was the announcement of PrEPX, a new public health research study supported by Alfred Health, the Victorian Government and the Victorian AIDS Council. This study will expand access to pre-exposure prophylaxis (‘PrEP’) medication to prevent HIV infection in people who are at high risk.
(Page 26 )
Research through partnership
This year’s achievements included care to prevent HIV infection, hope for those suffering severe asthma and dementia and a breakthrough in fighting blood cancer. We continued to attract a high level of funding from the National Health and Medical Research Council.
(Page 27)
Alzheimer’s drug trial success
Early research results of Anavex 2-73, a drug which aims to address the symptoms of dementia, are positive. Trials at Caulfield Hospital are using Anavex, which, unlike current medications, is the only drug designed to both relieve symptoms and slow the disease’s progression. The first phase of the trial began in December 2014 and the next steps will involve further research with a larger group of participants in 2017.
